You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Last Updated: December 4, 2023


✉ Email this page to a colleague

« Back to Dashboard

The small molecule drugs covered by the patents cited in this case are ⤷  Try a Trial , ⤷  Try a Trial , ⤷  Try a Trial , and ⤷  Try a Trial .


Date Filed Document No. Description Snippet Link To Document
2013-02-20 1 . 7,932,241 (“the ‘241 patent”) directed to certain approved presentations for zoledronic acid. 5. Upon…Novartis’ patent rights can be enforced 4. The three patents awarded to Novartis by the U.S. Patent and Trademark…are: U.S. Patent No. 8,324,189 (“the ‘189 patent”) directed to oncology methods, U.S. Patent No. 8,052,987…ACTION 2. This is an action for patent infringement under the patent laws of the United States, Title…987 patent”) directed to methods for treating abnormally increased bone turnover, and U.S. Patent No. External link to document
2013-03-27 146 Exhibit 2 one Pozen patent (U.S. Patent 6,926,907—“the ‘907 patent”) and five AstraZeneca patents (not at issue… responses with regard to the ‘907 patent only. The ‘907 patent has 55 claims. On November 17, 2011…907 patent. Subsequently, Plaintiffs further narrowed their asserted claims of the ‘907 patent to …VIMOVO® drug prior to the expiration of Plaintiffs’ patents. Id. DRL is the first ANDA filer for…dkt. nos. 41 and 82. A. The ‘907 Patent Plaintiffs seek leave to amend their External link to document
2013-04-30 225 primarily on the assertion of U.S. Patent No. 7,932,241 (“the ’241 patent”) in both the 2012 Case and …U.S. Patent No. 8,052,987 (“the ’987 patent”) and U.S. Patent No. 8,324,189 (“the ’189 patent”), which…and the February 2013 Case. The ’241 patent is the only patent from which Novartis asserted claims in…which are method of use patents asserted in the 2013 Cases, the ’241 patent is directed to the packaging…to improperly skirt the Local Patent Rules and revive the ’987 patent in the 2012 Case. Wockhardt is External link to document
2013-05-13 236 respect to U.S. Patent Nos. 7,932,241 and 8,052,987. Hospira alleged that these patents are invalid, …must include, among other things, the patent number of any patent that claims the drug or a method of… THE ’241 PATENT 14. The ’241 patent was issued on April 26, 2011, to…of using” zoledronic acid and is a patent for which a claim of patent infringement could reasonably … THE ’987 PATENT 20. The ’987 patent was issued on November 8, 2011, External link to document
2013-05-13 237 Novartis sued Wockhardt on U.S. Patent No. 8,052,987 (“the ’987 patent”) in Count II of the 2012 Case…fact that Novartis now has patent disputes regarding the ’987 patent with additional defendants …avoid this Court’s Local Patent Rules by re-asserting the ’987 patent in a new case. Perhaps because… claims of the ’987 patent, thereby waiving its ability to assert that patent against Wockhardt in… Novartis was aware that U.S. Patent No. 8,324,189 (“the ’189 patent”) had been allowed, and Novartis External link to document
2013-05-14 239 REDACTED - Novartis Opposition to Wockhardts Motion to Dismiss infringement of U.S. Patent No. 8,052,987 (the “’987 patent”). That patent covers methods of treating…under the Local Patent Rules, to add claims from the ‘987 patent. Even though that patent has always been…infringement of the ‘987 patent. Novartis has thus sued these defendants under the U.S. patent laws, 35 U.S.C… Novartis’s patent rights. So Wockhardt instead took the position that the ‘987 patent is invalid …financial losses. The ‘987 patent is one of the three patents at issue in this case. But the theory External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.